Breaking the Deadlock Over Destruction of the Smallpox Virus Stocks

Hopkins D . The Greatest Killer: Smallpox in History. Chicago: University of Chicago Press, 2002.

Tucker JB . Scourge: The Once and Future Threat of Smallpox. New York: Grove/Atlantic, 2001.

Henderson DA . Smallpox: The Death of a Disease. Amherst, NY: Prometheus Books, 2009.

Fenner F , Henderson DA , Arita I , Ježek Z , Ladnyi ID . Smallpox and Its Eradication. Geneva: World Health Organization, 1988; 1340.

Mahy BW , Almond JW , Berns KI et al. The remaining stocks of smallpox virus should be destroyed. Science, 1993; 262:1223–1224.

Joklik WK , Moss B , Fields BN , Bishop DH , Sandakhchiev LS . Why the smallpox virus stocks should not be destroyed. Science, 1993; 262:1225–1226.

Alibek K , Handelman S . Biohazard: The Chilling True Story of the Largest Biological Weapons Program in the World. New York: Random House, 1999; 107–122.

Gellman B . 4 nations thought to possess smallpox: Iraq, N. Korea named, two officials say. Washington Post, November 5, 2002; A1.

Henderson DA , Inglesby TV , Bartlett JG et al. for the Working Group on Civilian Biodefense. Smallpox as a biological weapon. JAMA, 1999; 281,22:2127–2137.

Institute of Medicine of the US National Academies. Assessment of Future Scientific Needs for Live Smallpox Virus. Washington, DC: National Academies Press, 1999.

White House . Office of the Press Secretary. White House statement on destruction of stocks of smallpox virus. April 22, 1999.

World Health Organization. Smallpox eradication: destruction of variola virus stocks. A52.A/Conference Paper No. 1, May 20, 1999.

Author's telephone interview with Dr. Kenneth Bernard, former White House official. May 17, 2010.

Fulginiti VA , Papier A , Lane JM , Neff JM , Henderson DA . Smallpox vaccination: a review, part II: adverse events. Clin Infect Dis, 2002; 37:251–271.

World Health Organization. Smallpox eradication: destruction of variola virus stocks. Weekly Epidemiol Rec, 2002; 77,5:34–38.

World Health Organization, Information Office. Statement to the press by the Director-General of the World Health Organization, Dr. Gro Harlem Brundtland. Statement WHO/16, October 2, 2001.

World Health Organization. Smallpox eradication: destruction of variola virus stocks. WHA55 15 May 2002.

Fowler J . World Health Organization reverses order to destroy smallpox stocks. Associated Press, May 18, 2002.

Broad WJ , Miller J . Government report says 3 nations hide stocks of smallpox. New York Times, June 13, 1999; A1.

Hammond E for Third World Network. Update on smallpox (variola) virus destruction, 63rd World Health Assembly. 17-21 May 2010. Geneva: Switzerland, 6–7.

World Health Organization. Smallpox eradication: destruction of variola virus stocksA59/102006.

Hammond E for Sunshine Project. Smallpox update: WHA delays decision on smallpox virus stocks. E-mail listserv report from Geneva, May 30, 2006.

World Health Organization. Smallpox eradication: destruction of variola virus stocks. WHA60 1 May 2007.

Institute of Medicine, Board on Global Health. Statement of task: Assessment of future scientific needs for live smallpox virus. October 2008.

Institute of Medicine, Board on Global Health. Live Variola Virus: Considerations for Continuing Research. Washington, DC: National Academies Press, July 2009.

World Health Organization. Major review of variola virus research, 1999-2010. http://www.who.int/csr/disease/smallpox/major_review/en/index.html. 2010 December 29.

World Health Organization, Advisory Committee on Variola Virus Research. Report of the eleventh meeting. Geneva: Switzerland 4-5 November 2009[WHO/HSE/GAR/BDP/2009.3]:5.

Yang G , Pevear DC , Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol, 2005; 79,20:13139–13149.

Duraffour S , Snoeck R , de Vos R et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antiviral Ther, 2007; 12,8:1205–1216.

Huggins J , Goff A , Hensley L et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother, 2009; 53,6:2620–2625.

Parker S , Handley L , Buller RM . Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol, 2008; 3,6:595–612.

Jordan R , Tien D , Bolken TC et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother, 2008; 52,5:1721–1727.

World Health Organization. WHO Advisory Committee on Variola Virus Research. Report of the Twelfth Meeting. Geneva: Switzerland 17-18 November 2010[WHO/HSE/GAR/BDP/2010.5]:8.

Smee DF , Sidwell RW , Kefauver D et al. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother, 2002; 46,5:1329–1335.

Yang G , Pevear DC , Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol, 2005; 79,20:13144.

Purt D . Bavarian Nordic begins Invamune deliveries. Vaccine News Daily, May 18, 2010. http://vaccinenewsdaily.com/news/213090-bavarian-nordic-begins-imvamune-deliveries. 2010 December 29.

Food and Drug Administration. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Register, 2002; 67,105:37988–37998. http://frwebgate6.access.gpo.gov/cgi-bin. 2010 December 29.

Author's interview with Dr. Dennis Hruby. Chief Scientific Officer, SIGA Technologies: Washington, DC, July 21, 2010.

Jahrling PB , Hensley LE , Martinez MJ et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA, 2004; 101,42:15196–15200.

Jordan R , Hruby D . Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther, 2006; 4,2:286.

Bremen JG , Henderson DA . Poxvirus dilemmas—monkeypox, smallpox, and biologic terrorism. N Engl J Med, 1998; 339,8:558.

National Research Council. Sequence-Based Classification of Select Agents: A Brighter Line. Washington, DC: National Academies Press, 2010; 169.

World Health Organization. Scientific review of variola virus research, 1999-2010. Geneva: WHO, 2010Chapter 3: Variola genomics38. http://www.who.int/csr/resources/publications/WHO_HSE_GAR_BDP_2010_3/en/index.html. 2010 December 29.

Boyce N . Smallpox mixes make a stir. U.S. News and World Report, January 19, 2004; 64.

World Health Organization. WHO recommendations concerning the distribution, handling and synthesis of variola virus DNA, May 2008. Weekly Epidemiol Rec, 2008; 83,44:393–395.

Intelligence Reform and Terrorism Prevention Act of 2004, 18 USC Part I, Chapter 10, subsection 175c.

World Health Organization. Global smallpox vaccine reserve: report by the SecretariatA58/9April 7, 2005.